Olink-sponsored Science/AAAS webinar – now available on-demand!
Title: “Emerging liquid biopsy biomarkers: Predicting response and resistance to cancer immunotherapy” Original broadcast date: Wednesday, 9 October 2019
Speakers: Genevieve Boland, M.D., Ph.D., FACS Massachusetts General HospitalBoston, MA Evert Jan Van Limbergen, M.D., Ph.D.Maastro Clinic Maastricht, The Netherlands
During the webinar, the speakers will:
Explain how whole-plasma proteomic profiling in melanoma and non–small cell lung cancer (NSCLC) patients enables discovery of blood-based biomarkers to predict immunotherapy responses, including resistance and toxicity
Describe how changes in immune activation during immunotherapy and radiation could be tracked by differentially expressed plasma proteins
Clarify how proteomic and transcriptomic biomarkers along with tumor-based analyses can drive patient selection and provide clinically actionable information
Demonstrate the relationship of plasma biomarkers to overall survival and progression-free survival in patients with advanced melanoma undergoing immunotherapy
Answer viewer questions during the live broadcast.